ALFA Finder| Revenue growth | 8% YoY growth in FY26. |
|---|---|
| Margins | EBITDA margin expanded from 13.3% (FY25) to 16.6% (FY26). |
| Demand visibility | Strong pipeline with 4 new API launches per year. |
| Management confidence | High; citing improved plant utilization and yields. |
Growth
FY26 Revenue grew 8% to ₹650 Cr; EBITDA rose 35% to ₹108 Cr; PAT jumped 117% to ₹66 Cr.
Outlook
Launching 4 new molecules annually from FY27; targeting formulation scale-up and further debt refinancing.
Risks
Q4 revenue declined due to the West Asia crisis impacting API export dispatches in March.
Earnings Call filed with NSE, NSE: WANBURY. Summary written with AI assistance from the document.
Wanbury Ltd: key numbers
- Share price
- ₹193.46
- Market cap
- ₹676.5 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.9×Sector 43.7×
- Promoter holding
- 42.98%-0.04% QoQ
- FII holding
- 0.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wanbury Ltd
All →Wanbury Regulatory Approval
Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.
Wanbury Q2 FY27 Results: Net Profit ₹11.9 Cr, Down 21.7% YoY
Wanbury Ltd reported revenue from operations of ₹182.9 Cr (+14.2% YoY) and net profit of ₹11.9 Cr (-21.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.9 Cr · -21.7% YoY
Wanbury Business Update
Wanbury's Tanuku plant received an Australian TGA GMP certificate covering six APIs. This strengthens the company's global pharmaceutical manufacturing credentials.
Wanbury Board Meeting Date
Wanbury Limited has scheduled its Board Meeting for 4 Nov 2026 to consider unaudited half-year results. No financial figures or material decisions are disclosed in this advance intimation.
Wanbury Other Announcement
Wanbury Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Wanbury Business Update
Wanbury Limited received nine "No DMF Deficiency" letters from the USFDA for Metformin HCl. The company also expanded its business in Saudi Arabia and Mexico with an annual revenue potential of Rs 25 Crore.